< Back to latest news & events

AGRITECH + IP

Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

April 2025

A recent case in the US District Court for the Northern District of Texas (Dallas Division) once again highlights how important the initial pleadings and evidence in patent infringement cases can be.

The case is between David Austin Roses Ltd and GCM Ranch LLC[1] and is based on alleged willful infringement of US plant patents held by David Austin covering several varieties of roses, and corresponding trademark infringement. David Austin Roses Ltd is a major British rose breeding company. The varieties bred by David Austin are well known as the company has been established for a long time and consistently obtains PVR protection for its roses around the world, including under the US Plant Patent Act. They also typically file trademarks for the tradenames of each rose covered under a corresponding plant patent.

In this case, David Austin alleged that GCM Ranch infringed nine granted US plant patents by selling rose varieties that fall under the plant patent claims. However the evidence they provided in their pleadings was based mostly on screenshots of the rose products on the GCM Ranch websites resembling the patented varieties, and reviews indicating sale of the products to consumers.

In response, GCM Ranch argued that the evidence was not sufficient to prove patent infringement because David Austin failed to provide any explanation of how the alleged infringing plants were produced. According to USC 163, in the case of a plant patent, the grant shall ‘include the right to exclude others from asexually reproducing the plant, and from using, offering for sale, or selling the plant so reproduced, or any of its parts, throughout the United States’.  It was clear that David Austin demonstrated that the plant was being offered for sale and sold, but did not satisfy that said plants were proven to be asexually reproduced from the patented plant. GCM Ranch seized on this point of law in their response, as did the Court. Despite the striking similarities in the plants being sold to the protected varieties, and the agreement that GCM Ranch new of the plant patents at issue, the Court granted GCM Ranch’s motion to dismiss the plant patent infringement case. The Court stated that ‘even though the roses resemble one another, David Austin has failed to plausibly allege that GCM Ranch’s roses were asexually reproduced from David Austin’s roses. For example, David Austin did not allege how GCM Ranch was asexually reproducing the patented roses—i.e., whether they did so by grafting, budding, or layering’.

It is clear that for plant patent infringement in the US the pleadings must be sure to provide factual evidence of how the infringing plants were actually derived from the patented plant, in addition to evidence of sales of the infringing plants. It seems that simply alleging that the patented plant variety has been asexually reproduced is not enough. A full case should be presented at the pleadings stage to avoid surprising dismissal.

[1] https://archive.org/details/gov.uscourts.txnd.388559/gov.uscourts.txnd.388559.33.0.pdf


This post was written by Partner and Patent Attorney Punita Shah and Partner and Patent Attorney Ellie Purnell.

Latest updates

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Zombie Fashion Brands

Episode 4 Zombie Fashion Brands  

Read article